EUVIMEDEUVIMED entdecken
Crossref

From network prediction to in vivo validation: luteolin attenuates cholestatic liver injury in association with PI3K/Akt/GSK-3β signalling modulation

Yuxin Wu, Shiji Gong, Xin Wu, Wei Wang, Dongming Zhang, Jianxin Jia

Naunyn-Schmiedeberg's Archives of Pharmacology · 2026

DOI: 10.1007/s00210-026-05577-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Yuxin Wu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Baotou Central Hospital, Baotou, 014040, Inner Mongolia Autonomous Region, China. Hauptthemen laut MEDLINE: Luteolin, Glycogen Synthase Kinase 3 beta, Proto-Oncogene Proteins c-akt, Phosphatidylinositol 3-Kinases. Die Arbeit nennt 41 Literaturangaben. Gefördert von: Natural Science Foundation of Inner Mongolia Autonomous Region.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cholestatic liver disease (CLD) is characterized by inflammatory amplification, hepatic stellate cell activation and collagen deposition. Luteolin is a natural flavonoid with reported anti-inflammatory and anti-fibrotic activities. Here, network pharmacology, molecular docking and experimental analyses were integrated to examine the effects of luteolin in CLD, with a focus on PI3K/Akt/GSK-3β-associated signalling. Target prediction identified 181 putative luteolin targets and 4,403 CLD-related targets, with 88 overlapping genes. In a bile duct ligation (BDL) rat model, luteolin treatment was associated with lower serum injury indices, reduced histopathological damage, decreased collagen deposition and lower fibrosis-related readouts. Experimental analyses further showed that luteolin treatment was accompanied by lower phosphorylation-associated readouts along the PI3K/Akt/GSK-3β axis. Together, these findings support an association between luteolin treatment and attenuation of cholestatic liver injury and fibrosis, within a multi-target signalling context that includes PI3K/Akt/GSK-3β.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LuteolinGlycogen Synthase Kinase 3 betaProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesCholestasisAnimalsSignal TransductionMaleNetwork PharmacologyRats, Sprague-DawleyRatsMolecular Docking SimulationLiver

Stichwörter der Autor:innen

Bile duct ligationCholestatic liver diseaseLiver fibrosisLuteolinNetwork pharmacologyPI3K/Akt/GSK-3β signalling axis

Substanzen

LuteolinGlycogen Synthase Kinase 3 betaProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesGsk3b protein, rat

Autor:innen und Institutionen

  • Department of General Surgery, Baotou Central Hospital, Baotou, 014040, Inner Mongolia Autonomous Region, China.
  • Baotou Medical College, Baotou, 014040, Inner Mongolia Autonomous Region, China.
  • Department of Human Anatomy, Baotou Medical College, Baotou, 014040, Inner Mongolia Autonomous Region, China.
  • Key Laboratory of Human Anatomy, Education Department of Inner Mongolia Autonomous Region, Baotou, 014040, Inner Mongolia Autonomous Region, China.
  • Department of General Surgery, Baotou Central Hospital, Baotou, 014040, Inner Mongolia Autonomous Region, China. dongming721@163.com.
  • Department of Human Anatomy, Baotou Medical College, Baotou, 014040, Inner Mongolia Autonomous Region, China. jiajianxindx@163.com.

Förderung

  • Natural Science Foundation of Inner Mongolia Autonomous Region

Zitieren

APA

Wu, Y., Gong, S., Wu, X., Wang, W., Zhang, D., & Jia, J. (2026). From network prediction to in vivo validation: luteolin attenuates cholestatic liver injury in association with PI3K/Akt/GSK-3β signalling modulation. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-026-05577-2

Vancouver

Wu Y, Gong S, Wu X, Wang W, Zhang D, Jia J. From network prediction to in vivo validation: luteolin attenuates cholestatic liver injury in association with PI3K/Akt/GSK-3β signalling modulation. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-026-05577-2

BibTeX
@article{Wu2026,
  author = {Wu, Yuxin and Gong, Shiji and Wu, Xin and Wang, Wei and Zhang, Dongming and Jia, Jianxin},
  title = {From network prediction to in vivo validation: luteolin attenuates cholestatic liver injury in association with PI3K/Akt/GSK-3β signalling modulation},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2026},
  doi = {10.1007/s00210-026-05577-2}
}
Kostenlos starten →